Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 423.08M | 422.67M | 458.30M | 704.27M | 598.37M | 282.25M |
Gross Profit | 291.50M | 292.29M | 318.63M | 519.55M | 481.81M | 179.59M |
EBITDA | 113.24M | 143.39M | 186.77M | 398.96M | 385.70M | 131.78M |
Net Income | -1.28M | 19.52M | 61.59M | 244.07M | 220.78M | 39.28M |
Balance Sheet | ||||||
Total Assets | 1.52B | 1.77B | 1.74B | 1.70B | 1.56B | 1.33B |
Cash, Cash Equivalents and Short-Term Investments | 289.34M | 585.97M | 466.40M | 322.81M | 186.39M | 10.96M |
Total Debt | 351.90M | 650.46M | 655.77M | 662.77M | 758.20M | 775.48M |
Total Liabilities | 642.75M | 893.32M | 895.37M | 916.72M | 1.04B | 802.16M |
Stockholders Equity | 874.17M | 874.40M | 844.97M | 780.96M | 524.30M | 530.67M |
Cash Flow | ||||||
Free Cash Flow | 99.75M | 141.94M | 173.92M | 254.67M | 198.26M | 128.95M |
Operating Cash Flow | 101.11M | 143.07M | 177.53M | 255.32M | 200.03M | 128.97M |
Investing Cash Flow | -4.04M | -4.89M | -3.61M | -2.68M | -6.26M | -1.38B |
Financing Cash Flow | -315.65M | -18.61M | -30.33M | -116.22M | -18.34M | 1.26B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | 23.71B | 20.50 | 46.14% | ― | 2.94% | 4.57% | |
73 Outperform | 1.51B | 8.38 | 25.43% | ― | -0.38% | 35.78% | |
63 Neutral | 5.31B | 7.65 | -47.03% | 3.04% | -0.18% | -18.95% | |
63 Neutral | 1.29B | -21.47 | -94.46% | ― | -10.39% | 14.92% | |
56 Neutral | $960.60M | 77.05 | -0.15% | ― | -3.43% | -102.60% | |
51 Neutral | 936.61M | -12.85 | -23.18% | ― | 11.67% | 31.55% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% |
On August 20, 2025, Olaplex Holdings, Inc. acquired Purvala Bioscience, a Boston-based biotech company, for $10.5 million. This acquisition marks OLAPLEX’s first since its inception over a decade ago, underscoring its commitment to innovation in the haircare industry. The integration of Purvala’s bioinspired technologies is expected to enhance OLAPLEX’s product offerings, potentially leading to the development of next-generation, science-backed products. This strategic move is anticipated to strengthen OLAPLEX’s position in the market and benefit its stylist community and consumers.
The most recent analyst rating on (OLPX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Olaplex Holdings stock, see the OLPX Stock Forecast page.